Insider Selling: Insulet Co. (NASDAQ:PODD) EVP Sells 12,394 Shares of Stock

Insulet Co. (NASDAQ:PODD) EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Insulet Stock Down 0.6 %

Shares of NASDAQ:PODD opened at $277.20 on Friday. The stock has a market cap of $19.44 billion, a price-to-earnings ratio of 47.47, a PEG ratio of 3.47 and a beta of 1.22. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $282.86. The business’s 50 day moving average is $266.84 and its 200 day moving average is $234.68.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.13. The company had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same quarter in the previous year, the firm earned $0.71 earnings per share. On average, sell-side analysts forecast that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Blue Trust Inc. boosted its position in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares during the last quarter. Venturi Wealth Management LLC boosted its position in Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 133 shares during the last quarter. TD Private Client Wealth LLC boosted its position in Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 56 shares during the last quarter. Friedenthal Financial purchased a new position in Insulet in the fourth quarter worth $57,000. Finally, Versant Capital Management Inc boosted its position in Insulet by 106.1% in the fourth quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock worth $80,000 after purchasing an additional 157 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on PODD. Canaccord Genuity Group lifted their target price on Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Sanford C. Bernstein began coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. JPMorgan Chase & Co. lifted their target price on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a report on Thursday, December 12th. TD Cowen lifted their target price on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Finally, BTIG Research lifted their target price on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, Insulet has a consensus rating of “Moderate Buy” and a consensus price target of $272.81.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.